Penile Traction & Erectile Function

Penile traction therapy targets the structural tissue of the penis — specifically the tunica albuginea — through sustained mechanical loading that triggers cellular growth via mechanotransduction. Erectile function, by contrast, depends on penile vascular function: nitric oxide release triggers smooth muscle relaxation and arterial blood flow into the corpora cavernosa. Penile traction therapy and erectile function involve fundamentally different physiological pathways.

Many men considering penile traction therapy express concern about potential damage to erectile function. Penile traction therapy applies calibrated force — between 900 and 2,800 grams with devices like the SizeGenetics device — to the flaccid or semi-erect penis over extended wear periods of 4–6 hours per day. The sustained low-force mechanical loading remodels collagen fibers within the tunica albuginea without compressing or occluding the vascular structures responsible for erections.

Distinguishing penile traction therapy from erectile dysfunction devices is essential. Penile traction devices deliver sustained axial force for tissue remodeling over weeks and months. Vacuum erection devices create negative pressure to draw blood into the corpora cavernosa for temporary tumescence. Constriction rings maintain blood within the corpora cavernosa during intercourse. Each device category serves a distinct clinical purpose, and penile traction devices are not erectile dysfunction treatments.

No peer-reviewed clinical study has reported worsening of erectile function as a result of penile traction therapy. Across 15+ peer-reviewed studies involving over 1,000 patients, researchers have consistently documented stable or improved scores on the International Index of Erectile Function (IIEF) — a 15-item validated questionnaire measuring five domains of male sexual function that serves as the gold standard outcome measure in erectile dysfunction research — in men using penile traction devices.

Gontero and colleagues, publishing in BJU International (2009), conducted a phase II prospective study of 15 men using a penile extender device for 6 months. Gontero et al. recorded a mean length gain of 1.3 cm (0.5 inches) with no adverse effect on erectile function. IIEF domain scores remained stable from baseline to study completion, confirming daily traction at 4–6 hours did not impair erectile mechanisms.

Levine, Newell, and Taylor, publishing in the Journal of Sexual Medicine (2008) (PMID: 18373527), studied penile traction therapy for Peyronie's disease treatment in a single-center pilot study. Levine et al. documented improvements in penile curvature alongside stable erectile function outcomes. No participant experienced worsening of erectile status during the traction protocol.

Moncada and colleagues, publishing in BJU International (2019), conducted a controlled multicentre study of penile traction therapy in the stable phase of Peyronie's disease. Moncada et al. confirmed traction therapy was both effective and safe, with no deterioration of erectile function observed. Several participants with pre-existing mild erectile dysfunction reported improved functional erections as penile curvature decreased.

For men seeking evidence-based approaches to improving erectile quality naturally, penile traction therapy represents a non-pharmacological option. Several clinical studies associate penile traction therapy with improved IIEF scores — particularly when curvature correction reduces mechanical interference with erectile function.

Peyronie's disease patients represent an informative study population because many experience penile curvature and erectile dysfunction simultaneously. Penile traction therapy can improve functional erections by reducing curvature-related mechanical obstruction. Chung and Brock, publishing in Therapeutic Advances in Urology (2013), described the reorganization and remodelling of collagen fibres into uniform densely packed fibrils parallel to the axis of mechanical strain — restoring tissue architecture in Peyronie's disease patients.

Post-surgical penile rehabilitation after radical prostatectomy represents the clinical context where penile traction therapy most directly supports erectile function recovery. Radical prostatectomy, even with nerve-sparing technique, frequently causes post-surgical penile shortening of 1.0–2.0 cm (0.4–0.8 inches) and temporary or permanent erectile dysfunction. Penile traction therapy addresses the structural component — preserving penile length — while pharmacological and vacuum-based therapies target the vascular and neurological components of erectile recovery.

Toussi, Ziegelmann, Yang, and colleagues, publishing in the Journal of Urology (2021) (PMID: 34060339), conducted a randomized controlled trial of 82 men following radical prostatectomy. The traction group gained 1.6 cm (0.6 inches) versus 0.3 cm (0.1 inches) in controls (p<0.01). Toussi et al. also documented improved IIEF scores in the traction group. Among participants, 87% would repeat the therapy and 93% would recommend penile traction to other post-prostatectomy patients.

The clinical rationale for including penile traction therapy in post-prostatectomy rehabilitation protocols centers on tissue oxygenation and fibrosis prevention. After prostatectomy, periods of flaccidity caused by neuropraxia (nerve bruising) can lead to corporal smooth muscle atrophy and fibrotic changes within the tunica albuginea. As the tunica albuginea remodels under traction, the corpora cavernosa within benefit from improved structural support and maintained expansile capacity during recovery.

Hehemann and colleagues, in a 2019 Mayo Clinic review, examined the role of penile traction therapy in post-surgical recovery and confirmed traction as a safe adjunct that does not interfere with erectile rehabilitation outcomes. The review reinforced the growing clinical consensus that penile traction therapy preserves penile length without compromising erectile function recovery pathways.

Comprehensive penile rehabilitation protocols typically combine three modalities in a staged approach. Phosphodiesterase type 5 inhibitors (PDE5i) — such as sildenafil (Viagra) or tadalafil (Cialis) — are introduced early to promote nocturnal erections and corporal oxygenation. Vacuum erection devices provide mechanical tumescence to stretch the corporal tissue. Penile traction therapy adds sustained axial loading to maintain or restore penile length. Ziegelmann, Farrell, and colleagues at Mayo Clinic, publishing in the Journal of Urology (2019), described this multimodal approach to penile rehabilitation, confirming that each modality targets a different aspect of post-surgical recovery.

Mulhall and colleagues, publishing a systematic review of penile rehabilitation in the Journal of Sexual Medicine (2013), evaluated the evidence for various rehabilitation strategies following radical prostatectomy. The review confirmed that early intervention with multiple complementary therapies — including traction as an adjunct — produced better erectile function and length preservation outcomes than single-modality approaches or delayed intervention.

Post-Surgical Rehabilitation Timeline

Penile traction devices, vacuum erection devices, and constriction rings each serve distinct clinical purposes. Confusion between these device categories is common among patients, and understanding the differences is essential for appropriate treatment selection. A penile traction device is sometimes mistakenly called an "erection extender," but this is inaccurate — penile traction devices are tissue remodeling tools, not erection aids. Penile traction devices deliver sustained low-force tissue remodeling over weeks and months to increase penile length and correct curvature.

Penile traction devices and vacuum erection devices can be complementary within a treatment plan. A man using a vacuum erection device for erectile dysfunction management can also use a penile traction device for length preservation or curvature correction — at different times of day and for different clinical purposes. The comparison of ED devices provides detailed guidance on how each device category functions within comprehensive treatment protocols.

Men with erectile dysfunction can use penile traction therapy because penile traction devices are applied to the flaccid or semi-erect penis. Erectile status does not affect the ability to fit, wear, or benefit from a penile traction device. The mechanical loading that produces tissue remodeling acts on the tunica albuginea regardless of vascular engorgement or erectile capacity.

Men searching for supplements to address erectile difficulties often encounter products with limited clinical evidence. Penile traction therapy, by contrast, is supported by 15+ peer-reviewed clinical studies and delivered through an FDA-registered Class II medical device. While supplements target biochemical pathways with variable efficacy, penile traction therapy produces measurable structural tissue changes documented by validated IIEF assessments and objective length measurements.

Specific clinical populations with erectile dysfunction who have used penile traction devices successfully include post-prostatectomy patients (Toussi et al., Journal of Urology, 2021), Peyronie's disease patients with concurrent erectile dysfunction (Moncada et al., BJU International, 2019), and men with age-related erectile changes (Gontero et al., BJU International, 2009). In each population, penile traction therapy produced measurable structural gains without worsening erectile dysfunction symptoms.

Special considerations for men with erectile dysfunction using penile traction devices include comfort optimization during fitting. The SizeGenetics device features 58-way Multi-Axis Comfort Technology, which accommodates varying penile states during wear. Men with erectile dysfunction may find fitting the device simpler than men with frequent spontaneous erections, as the flaccid state is the recommended application state for all penile traction devices.

Consulting a healthcare provider before beginning penile traction therapy is recommended for all men, and particularly for men with erectile dysfunction. A urologist can evaluate whether penile traction therapy is appropriate as a standalone therapy or as part of a combined treatment protocol alongside pharmacological or device-based erectile dysfunction management. The dedicated guide to ED and penile traction therapy provides detailed protocols for men with concurrent erectile dysfunction. Men with severe erectile dysfunction or penile implants should discuss candidacy with a specialist before using any external penile device.

SizeGenetics is an FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark, with over 500,000 units sold worldwide since 1994. SizeGenetics delivers calibrated traction force between 900 and 2,800 grams, and the device is designed for safe use by men with varying erectile function status — including men actively managing erectile dysfunction with medication or devices.

SizeGenetics is compatible with phosphodiesterase type 5 inhibitors (PDE5i) including sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). The recommended approach is temporal separation: use the SizeGenetics device during the day for the prescribed 4–6 hours of traction therapy, and take PDE5 inhibitor medication at a separate time as prescribed by a healthcare provider. Penile traction therapy should never be applied to an erect penis, including erections induced by PDE5 inhibitor medication.

SizeGenetics is also compatible with vacuum erection device therapy. Men using a vacuum erection device for erectile dysfunction management can use the SizeGenetics penile traction device at a different time of day for structural remodeling purposes. The distinct mechanisms — negative pressure for temporary tumescence versus sustained axial traction for permanent tissue remodeling — do not interfere with each other when used at separate times.

The SizeGenetics 58-way Multi-Axis Comfort Technology was engineered to accommodate daily wear periods of 4–6 hours across varying penile states. Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the penile traction device, designed the original traction mechanism in 1994 at Danamedic ApS in Denmark. The medical team at Danamedic, led by Dr. Siana and founder Jes Bech Müller, provides ongoing clinical guidance for patients using SizeGenetics alongside other medical treatments.

Across 15+ peer-reviewed clinical studies involving over 1,000 patients, with 500,000+ SizeGenetics units sold worldwide, zero serious adverse events have been reported from penile traction therapy.